Clinical trial phase II of oral hebal compoenent (BMP) in patient with multiple sclerosis

Phase 2

• Conditions: Multiple Sclerosis.; Demyelinating diseases of the central nervous system; G35, G36,

• Registration Number: IRCT138803241696N2
• Lead Sponsor: Iran Rheumatism Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Age between 18 and 50
Multiple sclerosis diagnosis by Mac Donald criteria
EDSS more than six
Signing informed consent
Exclusion criteria:
Sever hepatic/ Renal or cardiac diease
Sever psychological disorders
Adminstration of IVIG, Mitoxantrone, Plasmapheresis or immunosupressive drug since three months before
Pegnancy or intention to pregnancy

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in MRI (Magnetic Resonance Imaging). Timepoint: start of treatment, 6th and 12th month. Method of measurement: Magnetic Resonance Imaging.

Secondary Outcome Measures

Name	Time	Method
EDSS. Timepoint: Start of Treatment, 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th, and 12th month. Method of measurement: Asking from patients.;MSIS quality of life questionnaire. Timepoint: Start of Treatment, 1st, 2nd, 3rd, 4th, 5th, 6th, 8th, 10th, and 12th month. Method of measurement: Completing the questionnaire.